April 18, 2018
Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors. Per Wold-Olsen and Brian Stuglik will bring additional late-stage development and commercialisation experience to the company should the AGM vote in favour of the proposal. In conjunction with the AGM the proposal is furthermore that Alan Hulme will be stepping down as Chairman after eight successful years and handing over to Per Wold-Olsen as successor.
Oncopeptides has over the last few years progressed from being a privatively held early-stage development company to a publicly listed biotechnology company engaged in pivotal trials and now preparing for stand-alone commercialisation in the field of haematology - oncology in the US and Europe. The Nomination Committee has therefore strived to further strengthen the profile of the Board of Directors with emphasis on commercial experience in the US pharmaceutical market.
“Oncopeptides has a very exciting and important product candidate in Ygalo® for patients in need. The product could have significant market potential in the US market. I am looking forward to joining the Oncopeptides’ Board and being part of the continued development of the company and in particular the commercial strategy based on my extensive experience in the pharmaceutical industry” said Per Wold-Olsen.
“Since joining the Board of Oncopeptides as Chairman in 2010 the company has advanced dramatically and is now progressing with the lead compound Ygalo® in the pivotal phase III study OCEAN. The development has been made possible through the substantial effort and teamwork of an excellent management and Board, together with the support of our committed long-term investors. The company is now at the stage of starting the build-up in the US preparing itself for potential product registration in 2020. I am pleased to be handing the chairmanship over to Per with his extensive US commercial experience for the next stage of the company’s development” said Alan Hulme.
Bio: Per Wold-Olsen
Per Wold-Olsen is a Norwegian citizen born in 1947. Per joined the pharmaceutical company Merck & Co Inc. (Merck Sharp & Dohme) in 1974. He has served as Managing Director of the Norwegian subsidiary, Vice President of the Scandinavian region and as Senior Vice President of Worldwide Human Health Marketing and President of Europe and the Intercontinental Region of Merck & Co. Inc. US. He was a member of the Management Committee during the year from 1994 to 2006. Per is chairman of the board of directors of GN Store Nord A/S and of MMV (Medicines for Malaria Venture). He also serves as board member of Gilead Sciences, Inc. Per holds a MBA. in Economics and Administration from Handelshøyskolen BI and a MBA. in Management and Marketing from the University of Wisconsin.
Bio: Brian Stuglik
Brian Stuglik is a US citizen born in 1959. Brian is the founder of Proventus Health Solutions Inc. and has over three decades of extensive experience in US and international pharmaceutical development, product strategy, and commercialization, with over 25 years of experience in the field of oncology. Proventus Health Solutions helps biotech companies integrate development and commercial considerations into a unified approach, leading to a successful launch and commercialization. Prior to Proventus, Brian served as Vice President and Chief Marketing Officer for the Oncology Global Marketing Division at Eli Lilly and Company until 2016. Brian was instrumental in developing the Oncology division of Eli Lilly and Company with the launch of GEMZAR and had subsequent success in developing and launching several other products, including ALIMTA, ERBITUX, and CYRAMZA. In addition, Brian has extensive experience in early drug development, new product planning and business development. Brian earned his Bachelor of Science in Pharmacy from Purdue University and holds memberships of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. Brian also serves on the Board of Directors and Compensation Committee for Verastem, Inc. (NASDAQ: VSTM).
For further information, please contact or visit www.oncopeptides.se:
Jakob Lindberg, CEO of Oncopeptides
Cell phone: +46 705 695 471
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone. +46 708 537 292
The information was submitted through the agency of the contact person above for publication at 09.00 CET on April 18th, 2018.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program of Ygalo® is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.